For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

For older adults who express more confidence in vaccine safety than younger groups, the past few months have brought some ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2R3, Canada Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada Department of ...

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

The number of Australians vaccinated against influenza is "worryingly low", health experts say, as new data reveal the winter ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

RSV monoclonal antibody, clesrovimab,” which was approved by the FDA yesterday, Leerink Partners LLC analyst Daina Graybosch said. Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...